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Although much is known about the underlying mechanisms of p53
activity and regulation, the factors that influence the diversity and
duration of p53 responses are not well understood. Here we describe
a unique mode of p53 regulation involving alternative splicing of the
TP53 gene. We found that the use of an alternative 3′ splice site in
intron 6 generates a unique p53 isoform, dubbed p53Ψ. At the mo-
lecular level, p53Ψ is unable to bind to DNA and does not transacti-
vate canonical p53 target genes. However, like certain p53 gain-of-
function mutants, p53Ψ attenuates the expression of E-cadherin,
induces expression of markers of the epithelial-mesenchymal transi-
tion, and enhances the motility and invasive capacity of cells through
a unique mechanism involving the regulation of cyclophilin D activity,
a component of themitochondrial inner pore permeability. Hence, we
propose that p53Ψ encodes a separation-of-function isoform that,
although lacking canonical p53 tumor suppressor/transcriptional
activities, is able to induce a prometastatic program in a transcrip-
tionally independent manner.
reactive oxygen species | cancer
An evolutionarily conserved transcription factor, p53 has originsthat can be traced back to the early metazoans, ∼700 Mya (1).
This transcription factor plays a critical role in regulating many
fundamental aspects of reversible and irreversible cellular stress
responses, genome surveillance, and suppression of oncogenic
transformation (1). In response to strong cellular stresses such as
DNA damage or oncogenic signals, p53 regulates the expression
of a large cohort of genes that affect cell cycle arrest, senescence,
and apoptosis (1). Recent work has uncovered additional roles
for p53 under basal physiological conditions, such as regulation of
development, reproduction, metabolism, and self-renewal capacity
(2–5). However, the factors that influence the diversity and dura-
tion of p53 responses are not well understood. Here we describe
a unique mode of p53 regulation that involves alternative splicing
of the TP53 gene. We found that the use of an alternative 3′ splice
site in intron 6 generates a previously uncharacterized p53 isoform
that we named p53Ψ. Interestingly, this isoform is highly expressed
in cells characterized by a CD44high/CD24low immune type. At the
molecular level, p53Ψ lacks major portions of the DNA-binding
domain, the nuclear localization sequence, and the tetramerization
domain, features that are normally present in full-length p53
(p53FL). Consequently, this isoform proved incapable of se-
quence-specific DNA binding and transactivation of canonical p53
target genes. However, expression of the p53Ψ isoform attenu-
ated the expression of E-cadherin, induced expression of markers
associated with epithelial-mesenchymal transition (EMT), and
enhanced the motility and invasive capacity of normal and
malignant cells. Consistent with a role of these features in
enhancing the prometastatic capabilities of cells, we observed
that in patients with early-stage nonsmall cell lung carcinoma
(NSCLC), expression of p53Ψ correlated with increased
probability of relapse following surgical tumor resection. Such
characteristics are similar to certain p53 gain-of-function mis-
sense mutants.
We also found that the reprogramming of cells toward acquisi-
tion of mesenchymal-like features—induced either by expressing
p53Ψ or p53 with gain-of-function mutations—is contingent on
increased production of reactive oxygen species (ROS) by virtue
of interaction with cyclophilin D (CypD), a mitochondrial matrix
peptidyl-prolyl isomerase known to modulate opening of the mi-
tochondrial permeability transition pore (mPTP). Hence, we pro-
pose that p53Ψ encodes a “separation-of-function” isoform that
lacks canonical p53 tumor suppressor/transcriptional activities but is
capable of reprogramming cells toward acquisition of mesen-
chymal-like features in a transcriptionally independent manner.
The remarkably similar activities of p53Ψ and certain p53 mutants
also suggest that the latter “highjack” a regulated and reversible
program (i.e., p53Ψ alternative splicing) that contributes to the bi-
ology of p53 mutations during tumorigenesis. Thus, in principle, this
implies a possible physiological origin for certain p53 mutations.
Results
p53ψ Is a Unique p53 Isoform Generated from Use of an Alternative
3′ Splice Site. In response to strong cellular stresses such as DNA
damage or oncogenic signals, p53 regulates the expression of
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a large cohort of genes that affect cell cycle arrest, senescence,
and apoptosis (1). However, recent analyses have uncovered
essential roles for p53 also under basal physiological conditions
such as regulation of development, reproduction, metabolism,
and self-renewal capacity (2, 4–6). In particular, a recent publi-
cation by Godar et al. suggests that p53 specifically represses
expression of CD44, a transmembrane glycoprotein that has
been shown to regulate cell growth and cell motility in a variety
of cells (6–10). Interestingly, increased expression of CD44 has
been observed in CD24low, non–marrow-derived cells in tissues
on injury. This observation prompted us to investigate whether p53
activity was deregulated in CD44high/CD24low cells. To investigate
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Fig. 1. Expression of p53ψ, a unique p53 isoform generated by the use of an alternative 3′ splice site, is enriched in CD44high/CD24low cells. (A) Schematic of
naphthalene lung injury model. (B) Lung cell suspensions were sorted by FACS at different time points after injury with naphthalene. CD31- and CD45-
negative cells were used to remove endothelial cells and bone marrow-derived cells, respectively. (Right) Accumulation of CD44high/CD24low cells over 21 d.
Values in the right upper corners represent percentage of CD44high/CD24low cells relative to CD31−/CD45− cells. (C) The table reports expression of multiple
p53 targets in CD44low/CD24high (CD44L) cells sorted from naphthalene-injured mice compared with levels in CD44high/CD24low (CD44H) cells. (D) RT-PCR
analysis of lung tissue extracts obtained at the indicated time points after naphthalene treatment using oligonucleotide primers to exons 6 and 8 (ex6-ex8;
Top) and primers specific for p53ψ (460-ex8; Middle). Actin was used for normalization. (E) Sequence analysis of the two PCR products amplified with p53
primers indicated the use of a unique splice junction between exon 6 and exon 8 in the shorter p53 transcript. (F) RT-PCR analysis of lung tissue obtained after
naphthalene treatment at the indicated time points using primers specific for p53FL and p53ψ . (G) RT-PCR analysis of liver tissue after CCL4 treatment using
oligonucleotide primers specific for p53FL and the p53ψ isoform at the indicated time points. Analyses of levels of TGF-β and IL-6 were used to confirm tissue
injury. See Fig. S2C for further details on primer design. (H) RNA FISH confirmed expression of p53ψ in CCL4-injured livers. Tissue sections were hybridized with
RNA FISH probes specific for p53ψ (red) and stained for smooth muscle actin (SMA, green) to highlight damaged area. DAPI (blue) was used as counterstain.
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this, we used a murine lung injury model induced by i.p. naph-
thalene administration (Fig. 1A). Naphthalene treatment results in
rapid necrotic changes within Clara cells of the terminal and
respiratory bronchioles due to conversion of the drug into
a toxic form by the cell-specific microsomal enzyme Cyp2F2 (11).
As shown in Fig. 1B, on single i.p. injection of naphthalene,
we observed an expansion of CD44high/CD24low non–marrow-
derived (CD45−) and nonendothelial (CD31−) cells that
increased in number in the lung in a time-dependent manner
after injury from near undetectable levels in the vehicle-treated
animals to almost 6% of total CD31−/CD45− cells by day 21.
Interestingly, consistent with our initial hypothesis, gene ex-
pression analysis of FACS cells on injury revealed a reduction
in the expression of known p53-regulated genes such as
CDKN1A, Triap1, Sens1, Sens2, Pgam1, Pgam2, Sco1, Sco2,
Tigar, and Gpx1 in CD44high/CD24low/CD31−/CD45− cells
compared with CD44low/C24high/CD31−/CD45− cells (Fig. 1C
and Fig. S1A).
Prompted by this observation, we evaluated expression of p53
in total lung tissue homogenates taken from naphthalene-treated
and untreated animals. RT-PCR analysis using primers spanning
exon 6 to exon 8 indicated a slower migrating p53 band in cell
extracts obtained from injured lungs, which intensified in the
days following naphthalene injection (Fig. 1D). Sequence anal-
ysis revealed no mutations in exons 6, 7, or 8 or in intron 6, but
indicated that this band was a unique p53 mRNA variant gen-
erated by the use of an alternative 3′ splice acceptor site within
intron 6 (Fig. 1E and Fig. S1B). We refer to this p53 variant as
p53 psi (p53Ψ). Comparison across species revealed that the
sequence surrounding the alternative 3′ splice acceptor site in
intron 6 is highly conserved (Fig. S1C). This observation is of
particular interest given that intronic sequences are usually
highly divergent (12). Using p53Ψ -specific primers, we verified
p53Ψ was enriched in CD44high/CD24low/CD31−/CD45− cells
compared with CD44low/C24high/CD31−/CD45− cells on lung
injury (Fig. S1 D and E).
To determine whether p53Ψ was unique to the naphthalene
lung injury model, we extended our analysis to other organs and
to an additional tissue injury model. Specifically we determined
the expression of p53Ψ in the thymus, salivary gland, small in-
testine, brain, heart, kidney, skeletal muscle, spleen, stomach,
liver, and lung, as well as in the liver by RT-PCR analysis, using
primers designed to amplify p53Ψ and the full-length p53
(p53FL) mRNAs (Fig. S1D). We were not able to detect ex-
pression of p53Ψ in any of the organs at steady state (Fig. S1F).
However, similarly to what we observed in the case of lungs of
naphthalene-treated mice (Fig. 1 D and F), p53Ψ was observed
in CCL4-injured livers (Fig. 1G). Using RNA FISH, we con-
firmed expression of p53Ψ in CCL4-treated livers and observed
that its expression was localized in the proximity of tissue lesions
(i.e., the SMA-α–positive areas; Fig. 1H and Fig. S1G).
In sum, these observations indicate the existence of a unique
p53 isoform generated through an alternative splicing event that
is conserved across species and whose expression appears par-
ticularly enriched on tissue injury.
p53Ψ Is Expressed in Human Tumors and Tumor-Derived Cell Lines.
Human tumor analyses have shown that TP53 is mutated in
approximately half of all cancers (13). Somatic p53 mutations
occur in almost every type of tumor, at rates ranging from 30%
to 50% depending on tumor type (13). Mutations are more fre-
quent in advanced-stage cancers or in cancer subtypes that are
highly metastatic (13). Hence, the generation of p53Ψ could, in
principle, represent an alternative mode of p53 regulation in tu-
morigenesis. To investigate this, we assessed expression of p53Ψ
and p53FL levels using RNA-FISH on a human tissue microarray
(TMA) comprised of NSCLC tissues from 233 patients mainly
with early-stage adenocarcinomas (Fig. S2 A and B). Lung tumor
samples were stained with p53Ψ -specific probes. Approximately
22% of tumors clearly expressed p53Ψ (Fig. 2A and Fig. S2 C–F).
Interestingly, the majority of tumor cores that were positive for
p53Ψ were constituted primarily of CD44high/CD24low cells (Fig.
2B and Fig. S2). Univariate Kaplan–Meier survival analysis in-
dicated that patients with tumors expressing p53Ψ displayed
a decrease in overall survival compared with the p53Ψ -low group
and to p53-null tumors (Fig. 2C and Fig. S2G). In principle this
suggests that the generation of p53Ψ does more than create a
p53-null state.
It has recently been shown that tumor cells characterized by
a CD44high/CD24low immune type can be generated through
epigenetic/stochastic events in virtually all tumor-derived cell
lines and primary tumors (14). Given the high abundance of
p53Ψ in cells of this immune type in NSCLC and in injured
normal tissues, we investigated whether stochastically generated
CD44high/CD24low cells also expressed p53Ψ . RT-PCR analysis
of FACS-sorted cells from multiple tumor-derived human cell
lines using primers specific for p53FL and p53Ψ revealed that
p53Ψ was expressed predominantly in the CD44highCD24low cell
fraction (Fig. 2D). Sequence analysis confirmed the identity of
this presumed p53 isoform as an ortholog of the murine p53Ψ
gene (Fig. S2H). In addition, Western blot analysis revealed the
presence of a band of the expected p53Ψ size in CD44high/
CD24low cell extracts (Fig. S2I).
Splicing is carried out by the spliceosome, a massive structure
comprised of five small nuclear ribonucleoprotein particles
(snRNPs) and a large number of auxiliary proteins that accurately
recognizes the splice sites and catalyzes the two steps of the
splicing reaction (15). The decisions as to which splice sites are
used and which exons are included involve intronic and exonic
RNA sequence elements (cis-regulatory elements) and their
cognate protein regulators (trans-regulatory factors) (15). Our
data indicate that a natural, regulated switch in p53FL/p53Ψ splice
site selection occurs in stochastically generated CD44high /CD24low
cells and in injured normal tissues. This observation suggests that
in physiological conditions, controlled changes in abundance or
activity of trans-acting factors modulate the p53Ψ alternative
splicing events. However, in tumors, in addition to the deregulation
of the proper splicing factor balance, the occurrence of genetic
aberrations affecting cis-regulatory elements could also result in
aberrant p53Ψ expression. The splicing reaction requires the
presence of a highly conserved AG intronic dinucleotide at the
intron/exon boundary at the 3′ acceptor site. Hence, mutations in
the normal acceptor site at the intron 6/exon 7 boundary (−1G to
A/T/C or −2A to G/T/C with respect to the splice junction) could
favor the use of the cryptic acceptor site in intron 6 generating the
p53Ψ isoform. To test this hypothesis, we probed the International
Agency for Research on Cancer (IARC) TP53 database for
mutations at the intron 6/exon 7 boundary. Our analysis indicated
that the G/T/C mutations at position c.673-2A indeed occur in
multiple tumors including NSCLC (Fig. 2E and Fig. S2L) and that
these are the most frequent intronic mutations observed in the
TP53 gene (Fig. S2M). Among different tumor types, these muta-
tions are particularly enriched in upper urinary tract transitional cell
carcinoma (UUTCC) (Fig. S2L). Mutation analysis of 172 UUTCC
samples indicated these are the most frequent TP53 mutations in
this type of cancer (Fig. 2F). Given the conservation of AG residues
at all splicing sites, the high frequency of mutations at the intron 6/
exon 7 boundary acceptor site clearly suggests a functional selection
of this particular mutation.
Several studies have demonstrated a significant correlation
between the spectrum of p53 mutation and exposure to certain
types of carcinogens. For example, transversions in codon 157,
although uncommon in other types of cancer, are mutation
hotspots in lung, breast, and head and neck cancers and are
associated with smoking in lung cancer patients. In the case of
UUTCC, the occurrence of carcinoma in this highly unusual
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location has been associated with dietary exposure to aristolochic
acid (16, 17). Following metabolic activation, aristolochic acid
reacts with genomic DNA to form aristolactam-DNA adducts
that generate A to T transversions with high frequency in the p53
gene (17). Because all patients with tissues part of the cohort
analyzed in our study had been exposed to aristolochic acid, this
could explain the prevalence of c.673-2A mutations observed in
this tumor compared with other.
To verify that the presence of mutation at position c.673-2A
alters p53 splicing, we generated a minigene containing the
genomic fragment from exons 5–8 under cytomegalovirus (CMV)
promoter control (Fig. 2G). Detection and analysis of minigene-
derived transcripts were achieved by RT-PCR. Consistent with
the observation that normal cells preferentially express p53FL,
the minigene expressed the expected transcript with the expec-
ted sequence at the exon/intron junction (Fig. 2H). However,
mutation of the invariant A residue to G at the 3′ acceptor
site of intron 6 resulted in the generation of a p53Ψ isoform
(Fig. 2H).
To provide further evidence that the presence of intron 6
mutations could result in the generation of a p53Ψ -like tran-
script, we extended our analysis to a NSCLC-derived cell line
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(HOP62) that was reported to harbor a c.673-2A to G mutation.
We verified the presence of the mutation by sequence analysis
(Fig. S2O) and confirmed expression of a p53Ψ -like transcript by
RT-PCR analysis using primers complementary to sequences
in exon 4 and exon 7 (Fig. 2I). Western blot analysis of HOP62
cell extracts with a p53 N-terminal antibody also indicated the
presence of a protein of 27 kDa, the size of the p53Ψ protein
(Fig. 2L).
Multiple alternative p53 isoforms generated by virtue of al-
ternative splicing mechanisms have been previously described
(Fig. S2P) (18). To determine whether p53Ψ co-occurs with any
of these p53 splicing isoforms, we performed RT-PCR analysis
using oligonucleotides spanning the entire p53 coding sequence
in cells harboring a WT p53 allele compare with cells harboring
a homozygous c.673-2A mutation (Fig. S2P). Although we
cannot exclude that in other cell types or under different ex-
perimental conditions p53Ψ may occur with other known p53
isoforms, the TA p53Ψ -α isoform was the main isoform expressed
in HOP62 cells.
p53ψ Is Devoid of Transcriptional Activity. Due to an early stop
codon, the p53Ψ isoform encodes a p53 protein that is devoid of
critical residues required for DNA binding, oligomerization, and
localization to the nucleus (Fig. 3 A and B). Indeed, when we
examined the cellular distribution of p53Ψ by immunofluores-
cence in HOP62 cells and in p53-null cells (H1299) ectopically
expressing p53Ψ and p53FL, we detected remarkable differences
(Fig. 3C and Fig. S3A). Whereas p53FL was mainly localized
in the nucleus, p53Ψ was excluded from the nucleus and pre-
dominantly localized in the cytoplasm in a partly punctate pattern.
We confirmed these observations by biochemical fractionation in
(wtp53) A549 cells ectopically expressing p53Ψ and p53FL (Fig.
3D). As expected, p53FL was found in nuclear fractions and p53Ψ
in cytoplasmic fractions.
Because the nuclear localization sequence and oligomerization
and DNA binding domains of p53 are critical for sequence-specific
DNA binding and transactivation of target genes (19), we rea-
soned that p53Ψ would be devoid of a canonical p53 transcription
activity. As a first step to provide experimental evidence for this
hypothesis, we ectopically expressed p53Ψ and p53FL in p53-null
cells (H1299) and measured expression of known p53 targets.
Although overexpression of p53FL was sufficient to augment
PUMA, TIGAR, and p21 mRNA (Fig. 3E) and p21 protein levels
(Fig. S3B), overexpression of p53Ψ failed to elicit such a response.
These observations prompted us to directly compare p53Ψ and
p53FL transcriptional activity. To this end we measured the acti-
vation of a p53-responsive promoter in cells ectopically expressing
either p53FL or p53Ψ. As shown in Fig. 3F, luciferase reporter
assays using a synthetic p21CIP1 promoter (e.g., p21CIP1-luc)
confirmed that p53Ψ was transcriptionally inactive.
It seemed possible, however, that p53Ψ could affect p53 target
gene transcription by acting in a dominant negative fashion (e.g.,
by titrating p53 interacting proteins). Hence we sought to de-
termine whether ectopic expression of p53Ψ in cells expressing
p53FL (A549 cells) would modify the expression of p53 target
genes. Because in principle a putative dominant negative effect
of p53Ψ could be promoter specific, in addition to PUMA, BAX,
and p21, we extended our analysis to a broader array of p53 targets
(i.e., tiger, sod2, sgo2, cycg2, sharp1, gpx1, sens1, and sens2). How-
ever, no differences in the expression of any of these p53 targets
were observed in cells harboring WT p53FL on overexpression of
p53Ψ, either in basal conditions (Fig. S3D) or on stimulation with
doxorubicin (Fig. 3G).
In sum, based on this experimental evidence, we concluded
that p53Ψ is devoid of transcriptional activity. Thereby, in prin-
ciple, promoting the generation of p53Ψ at the expense of p53FL
could represent a unique physiologically relevant mode to limit
p53 tumor suppression function. Indeed, in cells expressing
p53Ψ, we consistently observed decreased expression of p53
target genes and increased expression of genes repressed by
p53 (Fig. 1C).
p53ψ, Like Certain p53 Gain-of-Function Mutations, Is Sufficient to
Reprogram Epithelial Cells Toward the Acquisition of Prometastatic
Features. Somatic alterations of the p53 tumor suppressor gene
located on chromosome 17p often occur in cancers and are
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p53ψ protein isoform. Equal amounts of whole cell lysate (T) and cytoplasmic
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using an antibody directed against the N-terminal domain of p53 (DO1).
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clear fractions, respectively. (E) The chart represents expression of known
p53 targets (p21, Puma, Tigar) in H1299 cells ectopically expressing vector,
p53ψ, and p53FL. mRNA levels were quantified by SYBR green-based real-
time RT-PCR in tetracycline inducible p53-null cells (H1299) ectopically
expressing p53FL or p53Ψ on induction with doxycycline (0.5 μg/mL) for 5 d.
Columns represent relative expression values (P < 0.0001, Student t test).
Levels of expression of p53FL and p53Ψ are provided in Fig. 3A. (F) A dual
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p53ψ fails to activate the synthetic p53-responsive promoter p21Cip1-luc.
Luciferase activity was normalized to Renilla activity. Data shown are rep-
resentative of three independent experiments (P = 0.03241). Cells were
treated with doxycycline (0.5 μg/mL) for 3 d before the assay. (G) p53ψ is
unable to modify the transcriptional activity of p53FL. Ectopic expression of
p53Ψ in cells expressing endogenous p53FL (A549 cells) did not induce ex-
pression of known p53 targets. To increase p53 activity cells were treated
with the DNA damaging agent doxorubicin for 24 h. The chart represents
relative mRNA levels of the indicated p53 targets on treatment with doxo-
rubicin (1 μM). Data shown represent relative (compared with actin) ex-
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state (Fig. 3C). Expression levels of p53FL and p53Ψ are provided in Fig. 3C.
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associated with poor prognosis (20). In these tumors, p53 muta-
tions disable p53-mediated inhibition of proliferation and pro-
motion of apoptosis in response to stress (20). In addition,
missense p53 mutations may have gain-of-function activities that
lead to an increased metastatic spread (21). The observed de-
crease in average disease-free and overall survival times in
patients with tumors expressing p53Ψ (Fig. S2G) and the high
frequency of the c.673–2A to G mutation in cancer patients and
in patients with UUTCC (Fig. 2F and Fig. S2M) suggests that
cancer-associated p53Ψ does more than create a p53-null state.
To test this hypothesis, we silenced p53Ψ expression in HOP62
cells. These mesenchymal cells are homozygous for the c.673-2A
to G mutation and inherently express exclusively a p53Ψ-like
isoform (Fig. 2I and Fig. S2O). On knockdown of p53Ψ in these
cells, we observed phenotypic and molecular changes distinctive
of cells undergoing mesenchymal to epithelial transition. Cells in
which p53Ψ expression was silenced lost the elongated appearance
typical of mesenchymal-like cells and instead acquired a cobble-
stone morphology characteristic of epithelial cells (Fig. 4A). At
the molecular level, these changes were associated with in-
creased expression of E-cadherin and diminished expression of
vimentin and the master regulators of the EMT program zeb1,
twist, and slug (Fig. 4B and Fig. S4A).
Conversely, ectopic expression of p53Ψ was sufficient to in-
duce morphological (Fig. 4C) and molecular (Fig. 4D and Fig.
S4) changes typical of cells undergoing EMT. These changes
were independent of their preexisting p53 status, as cells that
expressed p53FL (MCF7) and p53-null cells (H1299) both
showed decreased expression of E-cadherin but enhanced ex-
pression of vimentin, snail, zeb1, twist, and slug on p53Ψ expres-
sion (Fig. 4D and Fig. S4C).
TP53 is a tumor suppressor whose FL ectopic expression
transcriptionally activates stress responses. Although p53Ψ is
devoid of transcriptional activity, to further exclude the possi-
bility that the phenotypes we observed were due a selection
mechanism in response to cellular stress, we tested the effect of
p53Ψ expression in a tetracycline inducible A549-based cell line.
Like cells that constitutively express p53Ψ, transient expression
of p53Ψ in these cells was also able to reduce the expression of
E-cadherin (Fig. S4 C and D). Of note, changes in E-cadherin
were also apparent when analyzing its distribution. Whereas in
A549 cells at confluence, E-cadherin was mostly localized at cell-
cell junctions, in A549 cells ectopically expressing p53Ψ, E-cad-
herin was mainly localized in the cytoplasm (Fig. S4E).
In general, cells acquiring mesenchymal-like features tend to be
more motile and more invasive. Indeed, when we scored cell
migration in vitro in a standard wound-healing assay, A549 cells
expressing p53Ψ closed the cell monolayer opening more rapidly
than cells expressing p53FL (Fig. 4E). Similarly, A549 cells
expressing p53Ψ had enhanced capability to migrate through a
complex extracellular matrix compared with cells expressing p53FL
(Fig. 4F). The EMT transition, increased motility, and cell invasion
are important hallmarks of metastatic cells (22, 23). Hence, in
principle, the observed decrease in average disease-free and overall
survival times in patients with tumors expressing p53Ψ (Fig. 2C)
supports a general relevance of p53Ψ in reprogramming cells to-
ward the acquisition of prometastatic features.
Mitochondrial Localization of p53Ψ Is Required for Induction of the
Epithelial to Mesenchymal Transition. In the case of endogenous
p53FL, p53 mitochondrial localization has been observed under
stress conditions and on MDM2-induced p53 ubiquitination (24,
25). In particular, a growing body of evidence has highlighted the
importance of p53 localization to the mitochondria in mediating
certain transcription-independent activities of p53 (24, 26, 27).
Because p53Ψ was entirely excluded from the nucleus and devoid
of transcriptional activity, we undertook studies to determine
whether p53Ψ was localized to the mitochondria and, if so, whether
this was required for the p53Ψ-induced epithelial to mesenchymal
transition. Of note, when we examined the subcellular distribution
of p53Ψ by immunofluorescence and biochemical fractionation, we
observed that p53Ψ was partially localized into the mitochondrial
matrix under basal growing conditions (Fig. 5 A and B).
In eukaryotic organisms, about 10–15% of nuclear genes en-
code mitochondrial proteins (28). These proteins are synthesized
in the cytosol and are then translocated to the mitochondrial inner
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thelial morphology. Representative pictures of cells 4 d after transfection
with a mixture of two independent siRNA oligonucleotides targeting p53
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E-cadherin (ECAD) and vimentin (VIM), as well as the EMT master regulators
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siRNAs. No difference in Snail expression was observed. Data shown repre-
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0.0001, Student t test) as measured by SYBR green-based real-time RT-PCR.
Note these cells do not express p53FL. (C) Ectopic expression of p53Ψ
resulted in the acquisition of morphological features characteristic of cells
undergoing EMT. Scanning electron micrographs of representative MCF7
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provided in Figs. S4B and S3E, respectively. (D) The chart represents qRT-PCR
analysis of the canonical EMT markers E-cadherin (ECAD) and vimentin
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(E and F) Expression of p53Ψ in A549 cells leads to increased cell motility and
invasion. In E, the percentage of closure of a wound at the indicated time
points in a 2D cell monolayer is depicted. Each bar is the average of four
individual wounds. The histogram shows the mean value ± SD (P ≤ 0.0001 by
Student t test). The invasion potential of cells in F was determined in a
standard Matrigel invasion assay. Filter chambers were coated with 40 μL
Matrigel and invasion was assessed after 30 h. TGF-β–treated cells were used
as a positive control. Motility and invasion were determined in A549 cells
after induction for 5 d with doxycycline (0.5 μg/mL).
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or outer membranes or to the mitochondrial intermembrane space
or matrix (28). Although many proteins that translocate to the
mitochondrial matrix possess an N-terminal targeting sequence
called matrix-targeting sequence (MTS), many mitochondrial
precursors do not contain an MTS. For precursors without an
MTS, chaperone proteins may stabilize and assist in their trans-
port to mitochondria (28, 29). In the case of p53, the chaperone
protein Tid1 has been shown to interact with the N-terminal
domain of p53 and to mediate its translocation into the mito-
chondria matrix (30, 31). Tid1, also known as mitochondrial
Hsp40 (mtHsp40), is the mammalian homolog of the Drosophila
tumor suppressor Tid56 (32). Tid1 contains a conserved DnaJ
domain through which it interacts with the cytosolic Hsp70 family
of chaperone proteins that are also engaged in mitochondrial
transport of MTS-deficient proteins (32). DnaJ-like proteins
function as cochaperones with DnaK-like ATPases to promote
the (un)folding and translocation of polypeptides.
To determine whether Tid1 is involved in the translocation of
p53Ψ to mitochondria, we silenced Tid1 and determined its ef-
fect on the subcellular localization of p53Ψ. Biochemical frac-
tionation indicated that decreased expression of Tid1 was sufficient
to reduce the amount of p53Ψ transported into the mitochondria
without affecting the localization of CypD, a protein localized in
the mitochondrial matrix via an MTS (Fig. 5C). In further support
of Tid1-mediated p53Ψ mitochondrial localization, we generated
a p53Ψ construct that was constitutively localized to the mito-
chondria independent of Tid1 by virtue of the presence of an N-
terminal MTS tag (mito-p53Ψ). As predicted, the presence of an
MTS sequence was sufficient to overcome the effect of Tid1 si-
lencing (Fig. 5D).
The observation that Tid1 was required for p53Ψ mitochon-
drial localization prompted us to determine whether the trans-
location of p53Ψ into the mitochondrial matrix was in fact
required for p53Ψ-induced EMT. Indeed, silencing of Tid1 in
cells expressing p53Ψ resulted in a failure of p53Ψ to decrease
the expression of E-cadherin and in a decreased p53Ψ-mediated
increase in cell motility (Fig. 5E and Fig. S5A). Notably, no
difference in E-cadherin expression was observed in cells in
which Tid1 was silenced but p53Ψ was not expressed (i.e., vector-
transfected cells). Because the effect of Tid1 silencing on the
regulation of EMT could be independent of p53Ψ, we forced the
translocation of p53Ψ into the mitochondrial matrix in a Tid1-
independent manner (i.e., using mito-p53Ψ). Even in the ab-
sence of Tid1, mito-p53Ψ–expressing cells were characterized by
decreased E-cadherin levels (Fig. 5F). On the basis of this evi-
dence, we concluded that under basal conditions, p53Ψ is par-
tially localized to the mitochondrial matrix in a Tid1-dependent
fashion and that localization to the mitochondria is both neces-
sary and sufficient for induction of an EMT phenotype by p53Ψ.
p53ψ Interactionwith Cyclophilin D Is Sufficient to IncreaseMitochondrial
Pore Permeability and Reactive Oxygen Production.When localizing to
the mitochondria under apoptotic conditions, p53 modulates the
activities of antiapoptotic (Bcl-xL and Bcl-2) and proapoptotic
(BAK/BAX) members of the Bcl-2 family to regulate the integrity
of the outer mitochondrial membrane (27). p53FL interactions
with Bcl-xL/Bcl-2 on the one hand and BAK on the other hand
result in BAK oligomerization with subsequent outer membrane
permeabilization (MOMP) and release of cytochrome C and other
proapoptotic factors into the cytoplasm, mediating apoptosis (27).
Within the matrix, p53 has been shown to interact with MnSOD,
the primary antioxidant enzyme in mitochondria, and with CypD,
an obligatory activator of the mPTP that is closed in healthy cells.
To determine whether p53Ψ retained interacts with any of these
proteins, we conducted immunoprecipitation experiments. Because
CypD is localized in the mitochondrial matrix, we used as input
materials fractions containing outer mitochondrial membrane/
intermembranous space and inner mitochondrial membrane/
matrix. We found that mitochondrial p53Ψ was unable to bind to
BAX, BAK, and MnSOD (Fig. S5A) but reproducibly interacted
with CypD (Fig. 6A). Consistent with a failure to interact with
BAX and BAK, cells expressing p53Ψ were viable and did not
release cytochrome C from their mitochondria (Fig. S5E).
Vaseva et al. previously showed that the interaction with CypD
is mediated by a part of the DNA binding domain that is fully
retained in p53Ψ (24). To determine whether its residual DNA
binding domain (amino acids 102–243) mediated the p53Ψ in-
teraction with CypD and whether the interaction is direct, we
performed pull-down experiments. As shown in Fig. S5C, gluta-
tione S-transferase (GST)-tagged CypD selectively precipitated
recombinant p53Ψ; hence, the interaction appears to be direct.
Having shown that p53Ψ was able to bind directly to CypD, we
next explored a possible functional role for the p53Ψ/CypD in-
teraction in cells. Because the only known activity of CypD is
regulation of the mPTP opening, we measured the effect of p53Ψ
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Fig. 5. Mitochondrial localization of p53Ψ is required for p53ψ-induced
epithelial to mesenchymal transition. (A) Immuno-staining analysis of H1299
cells revealed a partial mitochondrial localization of p53Ψ (red). Mitochon-
drial GFP (pseudocolored in green in Upper) and cyclophilin D (CypD), a mi-
tochondrial matrix protein (pseudocolored in green in Lower) were used as
counterstains to highlight the mitochondria. The cell nuclei were stained
with DAPI (blue). (B) Western blot analysis of H1299 cells was used to
characterize the different submitochondrial fractions, indicating localization
of p53Ψ within the inner membrane/matrix fraction (im/ma). CypD and COX
IV staining were used to control for purity of the inner membrane/matrix
fraction, the high-mobility group box 1 (HMGB) antibody for the nuclear
fraction, PORIN antibody for the outer membrane fraction, and TUBULIN
antibody for the cytosolic fraction. (C and D) TID-1 is required for localization
of p53Ψ in the mitochondria. Biochemical fractionation followed by Western
blot analysis was used to analyze the distribution of (C) p53Ψ and (D) mito-
p53Ψ on TID-1 knockdown in p53Ψ-expressing A549 cells. At 72 h after
transfection with Tid-1–specific siRNA, p53Ψ mitochondiral localization was
determined. Analyses of CypD (a mitochondrial matrix protein) and p120
RasGAP (a cytoplasmic protein) localizations were used as controls for purity
of the mitochondrial fractions. (E and F) Western blot analysis of protein
extracts from A549 cells ectopically expressing (E) p53Ψ and (F) mito-p53Ψ
on inhibition of Tid1 expression indicate that Tid-1 is required for p53Ψ-
induced reduction of E-cadherin levels.
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on the mitochondrial permeability transition using calcein re-
lease, a highly selective indicator of sustained PTP opening in
situ (33, 34). Of note, MOMP and the Bax/Bak lipid pore are
completely incompetent for calcein release (35). In this assay,
cells are loaded with calcein (acetomethylester) together with its
quencher cobalt ions. Calcein freely diffuses throughout the cell
including into the mitochondrial matrix. However, the cobalt
quencher cannot diffuse across the inner mitochondrial mem-
brane, therefore quenching Calcein fluorescence everywhere except
in the mitochondrial matrix. Thus, calcein fluorescence comes
only from the matrix. Only on PTP opening will cobalt ions
gain access to the matrix and quench calcein, resulting in a
sharp drop of mitochondrial fluorescence, which can be mea-
sured by FACS or under the microscope (Fig. 6B). Notably, cells
expressing p53Ψ exhibited increased mPTP permeability relative
to cells that did not express this p53 isoform (Fig. 6 C and D).
This effect was CypD dependent, because treatment with cy-
closporine A (CsA), a highly selective pharmacological inhibitor
of CypD, reduced CoCl2-mediated quenching of calcein fluo-
rescence (Fig. 6 C and D). Although CsA also inhibits other
cytosolic cyclophilins in addition to mitochondrial matrix-specific
CypD, none play any role in the regulation of the mPTP pore
opening. As a control, cells that had been loaded with calcein
AM were treated with the ionophore ionomycin. In the presence
of ionomycin, we observed a rapid loss of mitochondria calcein
fluorescence in all experimental settings (Fig. 6 C and D).
An increase in time that mPTP is in the open state will result
in an increased outflow of electrons with increased accumulation
of ROS inside the mitochondria (36). To assess levels of super-
oxide in the mitochondria of live cells, we used the fluorogenic
dye MitoSOX (37). When added to cells, the MitoSOX reagent
is rapidly and selectively targeted to mitochondria, where Mito-
SOX is oxidized by superoxide. When exited with a light at 390-nm
frequencies, it emits red fluorescence. On loading with MitoSOX,
cells expressing p53Ψ exhibited increased MitoSOX staining com-
pared with p53FL-expressing cells and/or vector control (Fig. 6 E
and F). Consistent with increased mPTP opening mediated by
the interaction of p53Ψ with CypD, the increased MitoSOX fluo-
rescence was again decreased on inhibition of CypD with CsA
(Fig. 6 E and F).
Recently, Vaseva et al. reported that on oxidative stress, p53FL
translocates to the mitochondrial matrix and triggers sustained
mPTP opening by engaging in a physical interaction with CypD,
thereby inducing necrotic cell death (26). Confirming Vaseva
et al., when we forced p53FL into the mitochondrial matrix by
generating an N-terminal MTS fusion protein, we observed mas-
sive cell death. However, this was not the case when we expressed
either mitochondria-targeted p53 gain-of-function mutants or p53Ψ
either in p53-null cells or in cells expressing p53FL (Fig. S5D).
We did not observe major differences in CypD binding or in
mitochondrial permeability when p53FL, p53Ψ, and p53 gain-of-
function mutants were compared, suggesting that interaction
with CypD and/or an increased mitochondrial permeability, al-
though required for mitochondrial p53FL-mediated cell death, is
not sufficient but requires oxidative damage.
CypD and ROS Are Required for EMT Induction by p53ψ and p53 Gain-
of-Function Mutants. Although initially considered to be detri-
mental to cells, recent studies suggest that ROS are necessary for
the activation of multiple cellular pathways and for induction of
different cell states (38, 39). Specifically, increased levels of ROS
induce EMT and increase the metastatic competence of cells
(40). To determine whether CypD and ROS have a causative
role in EMT mediated by p53Ψ, we modulated CypD and ROS
levels in cells ectopically expressing p53Ψ (A549, MCF7, and
H1299) and determined their effects on expression of EMT
markers and cell invasion. Silencing CypD with either of two
siRNAs (Fig. 7A) or pharmacologically inhibiting CypD by
treating cells with CsA (Fig. 7B and Fig. S6A) was sufficient to
prevent EMT and to diminish cell motility in cells expressing
p53Ψ (Fig. 7C). As in the case of CypD, inhibition of ROS
production with N-acetyl cysteine (NAC) or Tempol, two well-
known ROS scavengers, augmented expression of E-cadherin
(Fig. 7E and Fig. S6C) and decreased invasive capabilities of
p53Ψ-expressing cells compared with control cells (Fig. S6D).
In contrast, low doses of H2O2 decreased the expression of
E-cadherin without compromising cell viability (Fig. 7D).
To exclude the possibility that ROS-induced EMT was in-
dependent of CypD in p53Ψ-expressing cells, we performed
epistasis experiments. Specifically, we measured E-cadherin ex-
pression on manipulation of ROS levels (e.g., by NAC treatment)
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Fig. 6. p53ψ interaction with cyclophylin D is sufficient to increase the
mPTP pore permeability and reactive oxygen production. (A) Immunopre-
cipitation analysis indicates an interaction between p53Ψ and CypD in the
mitochondrial fraction. The mitochondrial fraction of A549 ectopically
expressing p53Ψwas immunoprecipitated with a CypD-specific antibody and
probed with a p53 N-terminal antibody or as controls with CypD and Smurf1
antibodies. (B) Schematic of calcein AM assay. (C) The pictures depict rep-
resentative fluorescence microscopy images. A549 cells were loaded with
calcein at 10 nM, and fluorescence was detected by laser confocal micros-
copy after 15 min. Nonmitochondrial calcein fluorescence was quenched by
cotreatment with CoCl2. Treatment with the ionophore ionomycin (50 nM) is
shown as control. Cyclosporin A (CsA) was used at 2 mM. (D) The bars rep-
resent the percentage of drop of calcein fluorescence on quenching of cy-
tosolic calcein with CoCl2 in three independent experiments. Median calcein
fluorescence was assessed by FACS. Calcein was loaded at 10 nM and
detected at 515 nM after 15 min on excitation with Red HeNe at 495 nM.
Treatment with ionomycin was used as control to estimate basal fluores-
cence. FACS plots are provided in Fig. S6. (E) Representative fluorescence
microscopy images of A549 cells loaded with MitoSOX (1 μM). Images show
the fluorescence on excitation at 390 nm, mainly from the hydroxyethidium
derivative (red). DAPI (blue) was used as a counterstain. (F) The histogram
represents the quantification of the MitoSox-positive fractions in three in-
dependent FACS experiments from E.
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in cells ectopically expressing p53Ψ in the presence and absence
of CypD (Fig. S6B). We reasoned that if CypD and p53Ψ act on
parallel pathways, we would observe an additive effect of CypD
silencing and ROS inhibition. In contrast, if p53Ψ acts solely
through CypD, then CypD silencing would be sufficient to re-
duce ROS levels and no additive effect would be observed. In
agreement with our original hypothesis, silencing of CypD
blocked p53Ψ-induced EMT, and treatment of cells with NAC
did not increase E-cadherin expression in cells in which CypD
was silenced (Fig. S6B). Together these data strongly support
a model in which the p53Ψ interaction with CypD increases
mPTP permeability and increases ROS production that in turn is
necessary and sufficient for p53Ψ-induced EMT (model in Fig.
7F, Right).
Discussion
In summary, we provide evidence describing a unique, evolu-
tionarily conserved mode of p53 regulation involving alternative
splicing of the TP53 mRNA. The use of an alternative 3′ splice
site in intron 6 generates a previously uncharacterized p53 iso-
form. The protein product of this alternatively spliced mRNA,
p53Ψ, is incapable of sequence-specific DNA binding and trans-
activation of canonical p53 target genes but does induce the ac-
quisition of mesenchymal-like characteristics. Because p53Ψ is still
capable of binding to CpD and to regulate the mitochondria
pore permeability, we propose that p53Ψ encodes a separation-
of-function isoform. Importantly, our data also indicate that the
cytoplasmic p53 activity is sufficient to reprogram cells toward
acquisition of features associated with prometastatic phenotypes.
At the molecular level, we provide evidence suggesting that
p53Ψ-induced EMT does not depend on p53 transcriptional
activity but instead relies on its mitochondrial matrix localization
and its physical interaction with mPTP regulator CypD. In par-
ticular we found that ROS play a pivotal role as second mes-
sengers in mediating p53Ψ-induced EMT.
Regulation of ROS by p53 is not a novel concept. In fact, p53
has been shown to regulate the expression of many genes (e.g.,
Pig3, Tigar, Sens1, Sens2, Gpx1, Sco2, Bax, and Puma) that modify
the production of ROS in cells. Although p53Ψ ectopic expression
failed to modify the expression of any of these genes, the fact that
p53Ψ is generated at the expense of p53FL indicates that in cells
in which p53Ψ is generated as a result of an alternative splicing
events, ROS production can in principle be attributed to both
a CypD-dependent mechanism and to changes in the expression of
these p53FL target genes. Indeed, in cells that inherently express
p53Ψ (CD44high/CD24low cells sorted from injured lung), we ob-
served decreased expression of these p53 targets.
The observation that p53Ψ is inherently expressed in tumors
and during tissue injury is particularly intriguing. Generation of
cells bearing characteristics of those observed in wound healing
has been previously described in tumors and has been suggested
to reflect a maintenance in physiologic response of tumors to
regulatory pathways governing the tissue from which they are
derived (41, 42). In the 1860s, Virchow famously referred to
tumors as “wounds that never heal” (43). Hence, the remarkably
similar activities of p53Ψ and certain p53 mutants, which also
reduce E-cadherin expression and facilitate invasion in a CypD-
dependent manner, suggest that these p53 mutations highjack
a highly regulated program that during tissue injury leads to the
generation of p53Ψ. In principle, this implies a possible physio-
logical origin for certain p53 gain-of-function mutants.
Materials and Methods
Cell Culture. A549, H1299 (NCI-H1299), MCF7, PC9, H460 (NCI-H460), H4006
(NCI-H4006), and Phoenix-AMPHO cells were obtained from the American
Type Culture Collection (ATCC) repository. The Hop62 cells were obtained
from the National Cancer Institute (NCI) repository. All of the cell lines ex-
cept for Phoenix-AMPHO, HEK293T, and MCF7 were cultured in RPMI sup-
plemented with 5% (vol/vol) FBS, glutamine, penicillin, and streptomycin.
Phoenix-AMPHO, HEK293, and MCF7 cells were cultured in DMEM contain-
ing 10% (vol/vol) FBS, penicillin, streptomycin, and sodium pyruvate.
Antibodies and Reagents. The following antibodies were used in this study:
mouse anti-E-cadherin antibody (BD Transduction Laboratories), anti-p53
antibody (DO-1; Calbiochem), mouse anti–β-tubulin antibody (2-28-33; Santa
Cruz Biotechnology), rabbit anti-PARP antibody (46D11; Cell Signaling
Technology), rabbit anti-BAX antibody (D2E11; Cell Signaling Technology),
rabbit anti-PUMA antibody (#4976; Cell Signaling Technology), rabbit
anti-p21waf1/cip1 antibody (12D1; Cell Signaling Technology), anti-CpD
(ab110324; Abcam), anti-CD31 (clone 390; EBioscience), anti-CD45 (Clone
F
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Fig. 7. Cyclophylin D and ROS are required for EMT induction by p53ψ. (A)
Western blot analysis of A549 cells ectopically expressing p53Ψ on trans-
fection with two independent siRNA targeting cyclophilin D (CypD). (B)
Treatment with CsA, a highly specific and potent pharmacological inhibitor
of CypD, is sufficient to restore expression of E-cadherin to a level similar to
that observed in control cells and to reduce expression of EMT markers in
cells ectopically expressing p53Ψ. The chart represents qRT-PCR analysis of
the canonical EMT markers E-cadherin (ECAD) and vimentin (VIM), as well as
the EMT master regulators Snail, Slug, Twist, and Zeb1 in H1299 cells ec-
topically expressing p53Ψ on treatment for 5 d with 2 mM CsA. Data shown
represent relative (compared with actin) expression levels (mean ± SD, n = 6;
P < 0.0001, Student t test) as measured by SYBR green-based real-time
RT-PCR. Similar results were observed in MCF7 cells. (C) The chart represents
the motility of A549 cells ectopically expressing p53FL or p53Ψ after treat-
ment for 5 d with CsA. Cell motility was measured in a standard wound
healing experiment as previously described. The charts indicate the per-
centage of closure at 48 h in the presence or absence of 2 mM CsA. Each bar
is the average of four individual wounds. The histogram shows the mean
value ± SD (P ≤ 0.0001 by Student t test). (D) Treatment with low but in-
creasing concentrations of H2O2 is sufficient to decrease expression of
E-cadherin to levels similar to those observed in cell lines ectopically
expressing p53Ψ. mRNA levels of E-cadherin were assessed by SYBR green-
based real-time RT-PCR on treatment for 5 d with H2O2. Data shown rep-
resent relative expression compared with vector (mean ± SD, n = 6; P <
0.0001, Student t test). (E) Reduction of ROS levels is sufficient to enhance
expression of E-cadherin levels in cells expressing p53Ψ. Cells were treated
for 5 d with 10 mM NAC. Similar results were obtained in cells treated with
Tempol, another ROS scavenger (Fig. S6C). (F) Schematic of proposed
mechanism to explain p53Ψ-induced EMT. On acute oxidative stress, p53FL
was previously shown to interact with CypD and trigger necrotic cell death
by opening mPTP pore (Vaseva Cell 2012, Left).
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30-F11; EBioscience), anti-CD24 (Clone MI-69; EBioscience), anti-CD44
(Clone IM-7; Biolegend), and Tid-1 (Neomarkers MS-1564-P0). The chemical
reagents used for cell treatment were cyclosporin A from Sigma-Aldrich
(30024), calcein AM and MitoSox from Molecular Probes/Life Technologies,
H2O2 and doxorubicin hydrochloride from Sigma-Aldrich (#D1515), NAC
from Sigma-Aldrich (A9165), and tempol from Tocris (#3082). p53 siRNA
(GGGTTAGTTTACAATCAGC; GGTGAACCTTAGTACCTAA), Tid1 siRNA (CTA-
CATCCACATCAAGATA;GAAAGCCTATTATCAGCTT; AGCGAGTGATGATCCCTGT),
and CypD siRNA (AGGCAGATGTCGTCCCAAA; CGACTTCACCAACCACAAT) were
purchased from Invitrogen.
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